AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00883480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/day 1 x 4 cycles
Study NCT00883480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Docetaxel-Cisplatin 75 mg/day 1 x 4 cycles
Study NCT00883480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Cisplatin 75 mg/ day 1 x 4 cycles~Gemcitabine 1250 mg/ day 1 and 8 x 4 cycles
Study NCT00883480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150 mg/day x 21 days
Study NCT03419767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Patients under carotid revascularization surgery taking 6mg/day melatonin orally from 3 days before operation to 3 days after operation.
Study NCT03419767 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: blank
Description: Patients under carotid revascularization surgery without taking melatonin
Study NCT04543474 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Lactose Diet
Description: First, there was a run-in period (day 1-14), during which patients were randomly assigned by computer-generated bloc randomization to either the LLD or the LFD for 21 days (day 15-35). A dietician educated the participants on the first interventional diet. This phase was followed by a wash-out period of 21 days (day 36-56) with resumption of a normal balanced daily-life diet before crossing over to the alternate interventional diet (day 57-77). There were visits at the end of the washout phase with an instruction on the second interventional diet and at the end of the study.
Study NCT04543474 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low FODMAP Diet
Description: First, there was a run-in period (day 1-14), during which patients were randomly assigned by computer-generated bloc randomization to either the LLD or the LFD for 21 days (day 15-35). A dietician educated the participants on the first interventional diet. This phase was followed by a wash-out period of 21 days (day 36-56) with resumption of a normal balanced daily-life diet before crossing over to the alternate interventional diet (day 57-77). There were visits at the end of the washout phase with an instruction on the second interventional diet and at the end of the study.
Study NCT03927508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: r-tPA
Description: Pulse spray and infusion
Study NCT03927508 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Bashir™ Endovascular Catheter
Description: The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery and peripheral vasculature.
Study NCT01887899 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Study NCT01887899 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham stimulation
Study NCT04136353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: 2 x 300mg oral tablets twice daily for 96 weeks
Study NCT04136353 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: 2 oral tablets twice daily for 96 weeks
Study NCT04136353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luteinizing Hormone-Releasing Hormone Analog
Description: All participants are to receive standard background therapy with an LHRHA, as per standard of care. The choice of LHRHA is at the discretion of the treating clinician.
Study NCT04136353 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Luteinizing Hormone-Releasing Hormone Analog
Description: All participants are to receive standard background therapy with an LHRHA, as per standard of care. The choice of LHRHA is at the discretion of the treating clinician.
Study NCT04136353 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiotherapy
Description: All participants are to receive standard background therapy with curative-intent RT to the prostate or prostate bed as well as the pelvic lymph nodes using EBRT.
Study NCT04136353 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: External Beam Radiotherapy
Description: All participants are to receive standard background therapy with curative-intent RT to the prostate or prostate bed as well as the pelvic lymph nodes using EBRT.
Study NCT03071536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide Injection
Description: Furosemide 1.5 mg/kg intravenously at 3 hours post-reperfusion of kidney allograft
Study NCT04360616 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: imaging
Description: perform US and mammography examination
Study NCT05342129 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise bike
Description: exercise is to use an exercise bike, start pedaling on the first day, time setting: 20 minutes, speed: 2, and adopt passive mode. If you can complete the exercise on the first day, the time will be adjusted to 30 minutes on the second day. If you cannot complete the exercise on the first day, the time will still start from 20 minutes on the second day. The maximum time is 30 minutes. If you can complete 30 minutes of passive exercise for 3 consecutive days, the fourth day will be adjusted to active exercise. The entire exercise training is seven days a week, once a day, once a 30-minute, at least 5 days. Those who were discharged to the general ward continued to complete this exercise training for up to 28 days.
Study NCT00946946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Description: 2.0-2.5mg/kg/BW azathioprine /day and mesalazine placebo tablets
Study NCT00946946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalazine
Description: 4g Mesalazine tablets/day AND azathioprine placebo tablets
Study NCT00597103 — intervention group
Intervention type: OTHER
Intervention: Periodic Leg Movement Syndrome Assessment
Description: Subjects will wear and Actiwatch on both legs for three consecutive nights.
Study NCT03455686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 129Xe MRI
Description: Magnetic resonance imaging (MRI) using inhaled hyperpolarized 129Xe gas is a research approach for the non-invasive visualization and measurement of lung structure and function.
Study NCT03195569 — intervention group
Intervention type: DRUG
Intervention: QL1101
Description: targeted vascular endothelial growth factor (VEGF) monoclonal antibodies
Study NCT03195569 — intervention group
Intervention type: DRUG
Intervention: Avastin®
Description: targeted vascular endothelial growth factor (VEGF) monoclonal antibodies
Study NCT03195569 — intervention group
Intervention type: DRUG
Intervention: Paclitaxel
Description: 175 mg/m2, IV following investigational product on day 1 of each 21 day cycle.
Study NCT03195569 — intervention group
Intervention type: DRUG
Intervention: Carboplatin
Description: AUC 5 IV, following paclitaxel on day 1 of each 21 day cycle.
Study NCT02394561 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Secukinumab was supplied as 150 mg solution in pre-filled syringe for subcutaneous injection
Study NCT01312831 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B12 (cyanocobalamin)
Study NCT01312831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin B12 (cyanocobalamin)
Study NCT03728335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib Mesylate
Description: Given PO
Study NCT02421757 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fischell Transcutaneous Magnetic Stimulation Pain Treatment Device
Description: Transcutaneous Magnetic Stimulation
Study NCT02421757 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo Transcutaneous device
Study NCT03230188 — intervention group
Intervention type: OTHER
Intervention: functional Magnetic Resonance Imaging (research grade)
Description: Subjects will undergo a simulated and actual functional Magnetic Resonance Imaging scan.
Study NCT03230188 — intervention group
Intervention type: OTHER
Intervention: Cognitive Function Testing (non-diagnostic)
Description: Subjects will take non-diagnostic cognitive function tests
Study NCT03230188 — intervention group
Intervention type: OTHER
Intervention: Asthma and Psychological Questionnaires (non-diagnostic)
Description: Subjects will fill out asthma and psychological questionnaires (non-diagnostic)
Study NCT01188187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Custirsen
Study NCT01188187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT03452423 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACRFP
Description: Arthroscopic cartilage regeneration facilitating procedure (ACRFP) is a set of surgical procedures that combines resection of medial plica, medial and lateral capsular release, synovectomy of focal synovitis, and chondroplasty of loosened cartilage flaps as a rationale for the deliberate arthroscopic management of osteoarthritic knee.
Study NCT00544830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Given PO
Study NCT00544830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Description: Given SC
Study NCT00544830 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT00544830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00544830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Given via injection
Study NCT03433157 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hall technique
Description: Metal Stainless stain crown placed with Hall technique
Study NCT03433157 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional technique
Description: Metal Stainless stain crown placed with Traditional technique
Study NCT01499654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Half-dose of the Tc99-m sestamibi (Cardiolite)
Description: Researchers will administer half of the radiotracer (Cardiolite), obtain resting images, administer the remainder of the radiotracer and obtain a second set of resting images. Subjects will be given the same amount of radioactive material that would normally be given for this test; however, it will be administered in two ½ doses.
Study NCT01980641 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: All subjects received an educational intervention consist in an educational advice provides by the therapist to improve the adherence of the treatment.
Study NCT01980641 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone-based application
Description: Smartphone-based application group (SG) sample will have a reminder. The app will provide the advice previously given by the therapist in the participants' homes.
Study NCT01585558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ospemifene (Dose 1)
Study NCT01585558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ospemifene (Dose 2)
Study NCT01585558 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01188187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Study NCT01188187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study NCT01188187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Study NCT01188187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 8 mg by mouth twice a day for 3 days beginning one day before docetaxel administration to reduce the incidence and severity of hypersensitivity reactions and fluid retention.
Study NCT01188187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 8 mg by mouth twice a day for 3 days beginning one day before docetaxel administration to reduce the incidence and severity of hypersensitivity reactions and fluid retention.
Study NCT00678821 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Supervised aerobic exercise and educational lectures for 10 weeks
Study NCT00678821 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: Supervised aerobic exercise and educational lectures for 10 weeks
Study NCT05704972 — intervention group
Intervention type: OTHER
Intervention: the operating room environment risk
Description: in determining the risks they face in the operating room environment.
Study NCT03136406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Study NCT03136406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
Study NCT03136406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Study NCT03136406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione
Study NCT01731145 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SNUMAP
Description: Portable six-axis (tri-axial accelerometer and tri-axial gyroscope) motion sensing system
Study NCT02999581 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: C4 Extreme, C4 Extreme (without Advantra Z)
Study NCT03136406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
Study NCT03136406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
Study NCT03136406 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Recombinant human anti-VEGF IgG1 monoclonal
Study NCT03136406 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: avelumab
Description: Recombinant human anti-PD-L1 IgG1 monoclonal antibody
Study NCT03136406 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: Recombinant human super agonist interleukin-15 (IL-15) complex
Study NCT03136406 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aNK for Infusion
Description: NK-92 cells
Study NCT03136406 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-011
Description: Ad5 \[E1-, E2b-\]-CEA
Study NCT03136406 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-4000
Description: Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
Study NCT01468896 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV
Study NCT01468896 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Edodekin alfa
Description: Given SC
Study NCT02999581 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: C4 Extreme, C4 Extreme (without Advantra Z)
Study NCT01468896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02252523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Study NCT02544542 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rectum cooling system
Study NCT02544542 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyper-hypothermia blanket
Study NCT04081441 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inyenyeri clean cookstove and fuel system
Description: The Inyenyeri cooking systems includes a tier 4 clean cooking system with biomass pellets that are purchased through the unconditional cash transfer program in the refugee camp
Study NCT04081441 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Inyenyeri clean cookstove and fuel system
Description: The Inyenyeri cooking systems includes a tier 4 clean cooking system with biomass pellets that are purchased through the unconditional cash transfer program in the refugee camp
Study NCT04081441 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-ACT (Individual, Agency-Centered Training) workshop
Description: The I-ACT (Individual, Agency-Centered Training) empowerment workshop consists of behavioral exercises drawn primarily from positive psychology, that provide the tools to foster a growth mindset by allowing participants to understand the link between their thoughts, beliefs, and past actions to their future actions. Conducted in a workshop setting, this locally adapted version of the I-ACT curriculum consists of two days for women and a 1 day workshop for their male partners (as applicable)
Study NCT03669575 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega 7
Description: Three weeks omega 7 fatty acid nutritional supplement, approximately 900 mg/day
Study NCT03669575 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: omega 7
Description: Three weeks omega 7 fatty acid nutritional supplement, approximately 900 mg/day
Study NCT03669575 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Three weeks placebo fatty acids approximately 900 mg/day which does not contain omega 7
Study NCT03669575 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Three weeks placebo fatty acids approximately 900 mg/day which does not contain omega 7
Study NCT02404077 — intervention group
Intervention type: DRUG
Intervention: Clonidine
Study NCT01355718 — intervention group
Intervention type: DRUG
Intervention: repaglinide
Description: The dosage and frequency, as well as later changes to either dose, frequency or add-on medication (if applicable), will be determined by the physician, according to the patient's requirements.
Study NCT02999581 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: C4 Extreme, C4 Extreme (without Advantra Z)
Study NCT03749044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Educational Tool
Description: This tool is a modified version of the patient educational sheet elaborated and validated by You et al in collaboration with the Preeclampsia Foundation. This patient educational sheet graphically defines preeclampsia and its. A licensing agreement has been obtained from the Preeclampsia Foundation, with the rights to modify the educational tool for this RCT. The SLE-specific educational tool will consist in a sheet displaying the previously developed patient educational form on the recto. However, on the verso of the sheet, SLE-specific information related to the risk of preeclampsia in SLE pregnancies and the estimated efficacy of ASA in reducing preeclampsia risk in women at high risk are displayed.
Study NCT01669512 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Regimen
Description: ChAd63 ME-TRAP 5 x 1010 vp on Day 0 and MVA ME-TRAP 2 x 108 pfu on Day 56
Study NCT01669512 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low Dose Matrix M Regimen
Description: ChAd63 ME-TRAP 5 x 1010 vp mixed with Matrix M-1 25μg on Day 0 and MVA ME-TRAP 2 x 108 pfu mixed with Matrix M-1 25μg on Day 56
Study NCT01669512 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Standard Dose Matrix M Regimen
Description: ChAd63 ME-TRAP 5 x 1010 vp mixed with Matrix M-1 50μg on Day 0 and MVA ME-TRAP 2 x 108 pfu mixed with Matrix M-1 50μg on Day 56
Study NCT04138056 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: RSVPreF3 formulation 3
Description: One dose of RSVPreF3 formulation 3 vaccine administered intramuscularly in the left or in the non-dominant arm.
Study NCT04138056 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVPreF3 formulation 3
Description: One dose of RSVPreF3 formulation 3 vaccine administered intramuscularly in the left or in the non-dominant arm.
Study NCT04138056 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: RSVPreF3 formulation 2
Description: One dose of RSVPreF3 formulation 2 vaccine administered intramuscularly in the left arm.
Study NCT00946946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine placebo
Description: 4g Mesalazine tablets/day AND azathioprine placebo tablets
Study NCT00946946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalazine placebo
Description: 2.0-2.5mg/kg/BW azathioprine /day and mesalazine placebo tablets
Study NCT04228120 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-regulation programme
Description: The programme consisted of one 20-to-30-minute, face-to-face individual education session related to self-regulation and problem-solving processes that was performed in accordance with the patient's plan. Furthermore, eight 15- to 20-minute telephone follow-up counselling sessions were delivered twice per week for four weeks.